CHRISOFIX, headquartered in Switzerland, is a leading manufacturer of orthopedic splints/orthoses and other medical products. At the end of 2020, the CHRISOFIX Group was sold to professional private investors. ConAlliance acted as the exclusive M&A advisor for this transaction.
CHRISOFIX, headquartered in Switzerland, is a leading manufacturer of orthopedic splints/orthoses and other medical products. The company's value chain encompasses the design, development, manufacturing, and sale of a globally unique, patented product range in this specialized medical segment. The two legally independent entities, Chrisofix AG (Switzerland) and the production facility Chrisofix Hungary Ltd (Hungary), operate as closely linked independent companies that complement each other optimally in value creation. The first patent for the CHRISOFIX technology was developed and filed in 1995 by Dr. K. Bolla (MD), the founder. Since then, CHRISOFIX has continuously expanded its product range by developing new, patented orthotic and splint technologies and products.
The CHRISOFIX technology is a new fixation method that combines the advantages of circular (e.g., plaster, thermoplastic materials) and segmental fixations (splints and orthoses). The use of CHRISOFIX products makes splinting faster and more economical than previously developed fixation methods.
At the end of 2020, the CHRISOFIX Group was sold to professional private investors. ConAlliance comprehensively advised CHRISOFIX AG, CHRISOFIX Hungary Ltd., and founder Dr. Kalman Bolla as the lead advisor throughout the sales process.
The new management is committed to upholding the core values established by the founders and continuing to represent the outstanding product quality.
ConAlliance is one of the leading M&A advisory firms providing comprehensive support for corporate sales and acquisitions in the healthcare sector. Since its founding in 2011, ConAlliance has successfully managed over 100 mandates.
ConAlliance's industry expertise is highly specialized, focusing exclusively on corporate transactions within the healthcare sector.
Core competencies include medical technology, medical products, pharmaceuticals, nursing and hospital care, and other manufacturing and service companies in the global healthcare industry, as well as healthcare real estate.
Leadership of the ConAlliance Team
This transaction was led by Managing Partner Günter Carl Hober.
For more information about ConAlliance and our M&A advisory services, please visit www.conalliance.com.